Introduction
Continuous glucose monitors have gone from a niche accessory used mostly by people with type 1 diabetes on intensive insulin therapy to a category with genuine mainstream reach, including versions now cleared for sale directly to consumers without a prescription. Alongside them, automated insulin delivery systems that combine a sensor, a pump, and dosing software into a single closed-loop product have moved from experimental to standard of care for many patients. That growth has not been quiet on the regulatory side. It has created a distinct, fast-growing hiring niche for regulatory affairs professionals who understand how device, software, and in some cases drug-device combination rules apply to a product category that did not really exist in its current form a decade ago.
This is worth separating from the broader software-as-a-medical-device and AI-enabled device conversations that get most of the attention, because connected diabetes devices sit at an unusually complicated intersection: they are physical devices, they run software that increasingly makes real-time dosing decisions, they connect to smartphones and cloud platforms, and in the case of insulin pumps, they interact directly with a drug. Understanding why that combination creates so much regulatory work is the point of this piece.
Why This Category Is Regulatory-Heavy
A standalone glucose sensor is already a device with its own set of accuracy, biocompatibility, and manufacturing requirements. Add a companion app that displays readings and sends alerts, and you have a software component subject to its own set of expectations around usability and cybersecurity. Add automated dosing logic that adjusts insulin delivery based on the sensor's readings without a person actively deciding each dose, and you have moved into territory where a software error is not an inconvenience but a direct safety risk. Layer interoperability on top, letting one manufacturer's sensor talk to another manufacturer's pump or dosing algorithm, and the regulatory analysis has to account for how the combined system performs even though no single company controls every part of it.
Few other device categories require a regulatory affairs professional to hold device hardware rules, software and cybersecurity expectations, and drug-device interaction considerations in their head at the same time, on an ongoing basis rather than as an occasional cross-functional project.
The Regulatory Pathways Involved
Continuous glucose monitors have generally moved through FDA's device pathways as increasingly well-understood technology, with special controls established for the category once enough devices had cleared to define a reasonable baseline for accuracy and performance. Insulin pumps and automated insulin dosing systems have typically required a more rigorous premarket pathway given the direct safety stakes of automated dosing, though the exact classification and pathway depend on the specific product's design and its predicate history. A key development in this space has been FDA's interoperability framework, which allows individual components, an interoperable sensor, an interoperable pump, an interoperable dosing algorithm, to be authorized separately and then combined by patients and clinicians, provided each component meets defined interface and safety specifications. Regulatory affairs professionals in this niche need to understand not just how to get one company's product cleared, but how that product is expected to behave once it is paired with someone else's compatible component in the real world.
The Software and Cybersecurity Layer
Every connected diabetes device now ships with companion software, and increasingly that software is where the most safety-relevant functionality actually lives. FDA's expectations around cybersecurity for connected medical devices, including premarket documentation of a device's cybersecurity risk management and a plan for post-market vulnerability handling, apply directly to this category, and a security flaw in a connected glucose monitor or pump is a genuinely different kind of risk than a labeling error. Regulatory affairs professionals working in this space spend real time coordinating with software engineering and cybersecurity teams to make sure premarket submissions reflect current expectations, and increasingly need enough technical fluency to ask engineering the right questions rather than simply routing documents back and forth.
The Direct-to-Consumer Shift
The clearance of continuous glucose monitors intended for over-the-counter sale to people without diagnosed diabetes, marketed around general wellness and metabolic health rather than disease management, has opened an entirely new set of regulatory questions. Labeling written for a person managing a diagnosed condition under a clinician's guidance is a different task than labeling written for a general consumer making sense of glucose data on their own, and advertising and promotion for a consumer wellness product draws a different level of scrutiny than promotion aimed at a clinical audience. Regulatory affairs professionals supporting this shift need to understand not just device clearance requirements but the labeling and promotional review considerations that come with selling a medical-grade sensor as a direct-to-consumer product.
How This Differs From Broader Software-as-a-Medical-Device Work
It's tempting to fold connected diabetes devices into the general software-as-a-medical-device conversation, but the two are not quite the same job. A lot of SaMD regulatory work involves standalone software, a diagnostic algorithm, a clinical decision support tool, that runs on general-purpose computing hardware and has no physical device component to coordinate with. Connected diabetes devices force the hardware and software questions to be answered together: a sensor's physical accuracy under real-world conditions (temperature, movement, insertion site variability) interacts directly with how the software interprets and displays that data, and a dosing algorithm's safety case depends on both the reliability of the sensor feeding it and the soundness of the software logic itself. Regulatory affairs professionals in this niche cannot treat the hardware and software as separate submissions reviewed by separate specialists; the two have to be assessed as one integrated risk picture, which is a genuinely different skill than pure software regulatory work.
The Manufacturing and Supply Side
Demand for these devices has grown quickly enough that manufacturing scale-up and supply consistency have become their own regulatory concern. A sensor manufacturing change, a new lot of the enzyme or chemistry that makes the sensor work, or a shift in a component supplier can affect the device's real-world accuracy in ways that are hard to catch in a small validation batch but show up clearly once millions of sensors are in the field. Regulatory affairs professionals supporting this category increasingly work closely with manufacturing and quality on change control, assessing whether a proposed manufacturing change requires a new submission, a supplement, or can proceed under an existing letter to file, decisions that carry real consequences given how many patients depend on consistent sensor performance for their daily glucose management.
What Roles Are Actually Opening Up
Device manufacturers in this space are hiring regulatory affairs specialists and managers who can move fluently between hardware submissions, software documentation, and post-market surveillance for a product category that generates enormous volumes of real-world data given how many devices are worn continuously by patients. Post-market work is particularly significant here: a connected device that is worn 24 hours a day by hundreds of thousands of people generates complaint volumes and adverse event signals at a scale that requires dedicated regulatory and quality attention, not an occasional review. Companies are also hiring for roles that specifically bridge regulatory affairs and the interoperability ecosystem, people who understand how to position a component for compatibility claims with other manufacturers' cleared products.
Skills That Set Candidates Apart
Direct experience with software-containing devices, any prior work with FDA's cybersecurity premarket expectations, and comfort reading and applying special controls documents all transfer well into this niche. So does prior experience with combination products or drug-device interactions, given how central the drug-device relationship is to insulin delivery systems specifically. Beyond technical knowledge, this niche rewards people who can communicate clearly with engineering teams who may not have regulatory backgrounds, since so much of the actual risk in these products lives in software design decisions that regulatory affairs has to understand well enough to assess.
People coming from a general medical device regulatory background can move into this niche without starting over, but doing so well usually means deliberately building software and cybersecurity literacy rather than waiting for it to arrive through osmosis. Reading FDA's published guidance on premarket cybersecurity documentation closely, understanding the basic vocabulary of software risk classification, and getting comfortable in conversations with software engineers are all achievable through focused effort, and they meaningfully shorten the runway into a role in this space.
Conclusion
Connected diabetes devices are not a passing trend; they represent a durable shift toward automated, software-driven, patient-worn medical technology that will keep expanding as sensor accuracy improves and interoperability matures. For regulatory affairs professionals, that means a hiring niche that rewards fluency across device, software, and in some cases drug-device rules, and that is likely to keep growing as more of the category moves toward consumer-facing, over-the-counter use. It also previews a pattern that is likely to show up in other device categories over time, as more products combine sensors, software, and automated decision-making into a single patient-worn system. People who build real expertise in this specific niche now are, in effect, building a template for where connected medical device regulation across the broader device industry is headed, not just in diabetes care specifically.